X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   MYLAN
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
MYLAN
Dec-14
VENUS REMEDIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2183,802-   
Low Rs822,679-   
Sales per share (Unadj.) Rs365.61,301.5-  
Earnings per share (Unadj.) Rs1.5156.8-  
Cash flow per share (Unadj.) Rs37.9252.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.5647.0-  
Shares outstanding (eoy) m11.44378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x0.42.5 16.5%   
Avg P/E ratio x101.020.7 488.6%  
P/CF ratio (eoy) x4.012.8 30.8%  
Price / Book Value ratio x0.45.0 7.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7171,226,120 0.1%   
No. of employees `0001.025.0 4.1%   
Total wages/salary Rs m3240-   
Avg. sales/employee Rs Th4,100.719,698.4 20.8%   
Avg. wages/employee Rs Th318.00-   
Avg. net profit/employee Rs Th16.72,373.0 0.7%   
INCOME DATA
Net Sales Rs m4,183492,459 0.8%  
Other income Rs m20-2,871 -0.7%   
Total revenues Rs m4,203489,588 0.9%   
Gross profit Rs m812122,477 0.7%  
Depreciation Rs m41736,169 1.2%   
Interest Rs m38021,242 1.8%   
Profit before tax Rs m3562,195 0.1%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m182,615 0.7%   
Profit after tax Rs m1759,325 0.0%  
Gross profit margin %19.424.9 78.0%  
Effective tax rate %51.64.2 1,226.3%   
Net profit margin %0.412.0 3.4%  
BALANCE SHEET DATA
Current assets Rs m2,771432,936 0.6%   
Current liabilities Rs m1,931338,470 0.6%   
Net working cap to sales %20.119.2 104.6%  
Current ratio x1.41.3 112.2%  
Inventory Days Days12578 160.2%  
Debtors Days Days54107 50.1%  
Net fixed assets Rs m5,328113,929 4.7%   
Share capital Rs m11417,415 0.7%   
"Free" reserves Rs m4,1770-   
Net worth Rs m4,376244,801 1.8%   
Long term debt Rs m1,911365,708 0.5%   
Total assets Rs m8,428986,034 0.9%  
Interest coverage x1.13.9 27.8%   
Debt to equity ratio x0.41.5 29.2%  
Sales to assets ratio x0.50.5 99.4%   
Return on assets %4.78.2 57.6%  
Return on equity %0.424.2 1.6%  
Return on capital %6.613.6 48.4%  
Exports to sales %00-   
Imports to sales %20.50-   
Net fx Rs m-8580-   
CASH FLOW
From Operations Rs m46964,734 0.7%  
From Investments Rs m29-51,051 -0.1%  
From Financial Activity Rs m-464-17,057 2.7%  
Net Cashflow Rs m35-3,374 -1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.79 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: J.B.CHEMICALS  ELDER PHARMA  AUROBINDO PHARMA  BIOCON LTD  GLENMARK PHARMA  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 23, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ABBOTT INDIA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS